An update in the management of rheumatoid arthritis

Journal of the Pakistan Medical Association

Volumn 55, Issue 4, 2005, Pages 167-169

  Abid, Naushad ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYLCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

BIOLOGICAL ACTIVITY; CLINICAL TRIAL; CONCEPT FORMATION; DOSE RESPONSE; DRUG ANTAGONISM; HEALTH SERVICE; HUMAN; LYMPHOMA; MONOTHERAPY; NONHUMAN; PAKISTAN; PATHOGENESIS; PATIENT REFERRAL; PHYSICIAN; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUBERCULOSIS; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; METHODOLOGY; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; PAKISTAN; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; REFERRAL AND CONSULTATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23844435666     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Hameed K, Gibson G, Kadir M. The prevalence of rheumatoid arthritis in affluent and poor urban communities of Pakistan. Br J Rheumatol 1995; 34:252-6.
2. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug based treatment strategies. Arthritis Rheum 1996; 39:616-22.
3. Okada Y. Proteinases and matrix degradation. In: Rudy S, Harris ED, Sledge CB, EDS. Kelleys text book of rheumatology. 6th ed. Philadelphia: W. B. Saunders, 2001, pp. 55-72.
4. Bukahri M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register study, a large inception cohort. Arthritis Rheum 2002;46:906-12.
5. Choy EHS, Panayi GS. Cytokine pathway and joint inflammation in rheumatoid arthritis. N Eng J Med 2001;344:164-9.
6. Aletaha D, Ebert G, Nell VPK, Machold KP, Smolen JS. Practical Progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 2002;61:630-4.
7. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS, et al. Early referral recommendations for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
8. Lard LR, Visser H, Speyer I, Vander Horst Bruinsma IE, Zwinderman AH, Breedveld F, et al. Early versus delayed treatment in patients with recent onset rheumatoid arthritis: comparision of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
9. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
10. Ali AA, Iqbal MP, Hussain MA, Mehboodali N, Beg JA, Rahbar MH, et al. Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan. J Pak Med Assoc 1998;48:3-6.
11. Boers M, Verhoeven AC, Markusse HM, Vander Laar MA, Westhovens R, van Derderen JC, et al. Randomised comparision of combined step down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
12. O'Dell JR , Haire CE , Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxy chloroquine or a combination of all three medications. N Eng Med 1996;334:1287-91.
13. Wilder RL. Corticosteroids. In: Klippel JH, Crofford LI, Stone JH Primer on rheumatic diseases. 12th ed. Atlanta: the Arthritis foundation, 2001, pp. 593-8.
14. Alateha D, Smolen JS. Effectiveness profiles and dose dependent retentition of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 2002;29:631-8.
15. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p-75)-Fc fusion protein. N Eng J Med 1997;337:141-7.
16. Bathon JM, Martin RW, Fleischmann RM, Terser JR, Schiff MH, Keystone EC. A comparision of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med. 2001;344:6.
17. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receotor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 1999;340:253-9.
18. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlani JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti - tumor necrosis factor alpha monoclonal antibody combined with low dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
19. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Brudveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med 2000;343:1594-602.
20. Van de Putte LBA, Atkins C, Malaise M. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis . Arthritis Rheum 2002;46 (Suppl): S205. abstract.
21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH. Adalimumab, a fully human anti tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking methotrexate: the ARAMDA trial. Arthritis Rheum 2003;48:35-45.
22. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Eng J Med 2001;344:1099-100.
23. Keane J, Gershan S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Eng J Med 2001;345:1098-104.
24. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MH. Tumor necrosis factor antagonist therapy and lymphoma development: twenty six cases reported to the food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
25. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant Lymphomas in patients with rheumatoid arthritis and in their first degree relatives. Arthritis Rheum 2003;48:963-70.
26. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
27. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
28. Horal R, Saijo S, Taniko H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interlrukin-1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
29. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan T, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
30. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sasnowska A, Emery P, Close DR, et al. Efficacy of B-cell-Targeted therapy with rituximab in Patients with Rheumatoid arthritis. New Eng J Med 2004;350:2572-81.